JP2021529777A5 - - Google Patents

Info

Publication number
JP2021529777A5
JP2021529777A5 JP2020573342A JP2020573342A JP2021529777A5 JP 2021529777 A5 JP2021529777 A5 JP 2021529777A5 JP 2020573342 A JP2020573342 A JP 2020573342A JP 2020573342 A JP2020573342 A JP 2020573342A JP 2021529777 A5 JP2021529777 A5 JP 2021529777A5
Authority
JP
Japan
Prior art keywords
formulation according
formulation
polypeptide
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529777A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040129 external-priority patent/WO2020009992A1/en
Publication of JP2021529777A publication Critical patent/JP2021529777A/ja
Publication of JP2021529777A5 publication Critical patent/JP2021529777A5/ja
Pending legal-status Critical Current

Links

JP2020573342A 2018-07-02 2019-07-01 進行非小細胞肺癌の治療のための標的TGF−β阻害による組み合わせ療法 Pending JP2021529777A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693042P 2018-07-02 2018-07-02
US62/693,042 2018-07-02
US201962801014P 2019-02-04 2019-02-04
US62/801,014 2019-02-04
PCT/US2019/040129 WO2020009992A1 (en) 2018-07-02 2019-07-01 Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer

Publications (2)

Publication Number Publication Date
JP2021529777A JP2021529777A (ja) 2021-11-04
JP2021529777A5 true JP2021529777A5 (https=) 2022-07-08

Family

ID=69059780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573342A Pending JP2021529777A (ja) 2018-07-02 2019-07-01 進行非小細胞肺癌の治療のための標的TGF−β阻害による組み合わせ療法

Country Status (13)

Country Link
US (1) US20210115145A1 (https=)
EP (1) EP3817740A4 (https=)
JP (1) JP2021529777A (https=)
KR (1) KR20210028219A (https=)
CN (1) CN112638374A (https=)
AU (1) AU2019299318A1 (https=)
BR (1) BR112020026902A2 (https=)
CA (1) CA3105360A1 (https=)
IL (1) IL279862A (https=)
MX (1) MX2021000110A (https=)
SG (1) SG11202013190YA (https=)
TW (1) TW202019405A (https=)
WO (1) WO2020009992A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113968903A (zh) * 2020-07-24 2022-01-25 迈威(上海)生物科技股份有限公司 TGF-β RII突变体及其融合蛋白
CN114573701A (zh) * 2020-12-02 2022-06-03 上海华奥泰生物药业股份有限公司 抗PD-L1/TGF-β双功能抗体及其用途
CN117222413A (zh) * 2021-02-10 2023-12-12 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130110045A1 (en) * 2011-10-31 2013-05-02 Ming-Yuan Wu Single use intravenous therapy administering device with needle safety covers
BR112016014952A2 (pt) * 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
CN109640988A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
AU2017310027A1 (en) * 2016-08-12 2019-01-31 Merck Patent Gmbh Combination therapy for cancer
WO2018129331A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
JP2021527083A (ja) * 2018-06-13 2021-10-11 メルク パテント ゲーエムベーハー ステージiii nsclcの治療及びその治療に伴う病理学的状態の鎮静

Similar Documents

Publication Publication Date Title
JP2025020147A5 (https=)
Dorsey et al. Promising new molecular targeted therapies in head and neck cancer
JP2020508317A5 (https=)
US20180036395A1 (en) Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies
JP2016520082A5 (https=)
JP2021527083A5 (https=)
JP2013520442A5 (https=)
JP2019517498A5 (https=)
JP2016530280A5 (https=)
JP2023526259A5 (https=)
JP2021529777A5 (https=)
JP2022512851A5 (https=)
JP2023528206A5 (https=)
JP2018512402A5 (https=)
JP2022527334A5 (https=)
JP2021530502A5 (https=)
JP2021523096A5 (https=)
JP2022501332A5 (https=)
JP2021511344A5 (https=)
JP2021528399A5 (https=)
JP2024513247A5 (https=)
JP2022530599A5 (https=)
Kogure et al. A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: study protocol
JP2025504278A5 (https=)
JP2024519450A5 (https=)